Role of coagulation and fibrinolytic system in prostate cancer

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 3, 2003, Pages 301-308

  Kohli, Manish ^a,b   Kaushal, Varsha ^b   Mehta, Paulette ^b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Angiogenesis; Bleeding; Fibrinolysis; Hypercoagulability; Prostate cancer

Indexed keywords

PLASMINOGEN;

ANGIOGENESIS; ARTERY THROMBOSIS; BLEEDING TENDENCY; BLOOD CLOTTING; CANCER GROWTH; CANCER STAGING; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; VEIN THROMBOSIS;

BLOOD COAGULATION; FIBRINOLYSIS; HEMORRHAGE; HUMANS; MALE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; THROMBOPHILIA;

EID: 0038095540     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40968     Document Type: Review

References (84)

1. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-1101
2. De Voogt HJ, Smith PH, Pavone-Macaluso M, et al. Cardiovascular side effects of diethylstilbesterol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135:303-307
3. Adamson AS, Witheerow RO, Francis JL, Snell ME. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. Ann R Coll Surg Engl 1993;75:100-104
4. Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977;56:1-37
5. Blombäck M, Hedlund PO, Sawe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications? Thromb Res 1988;49(Suppl):111-121
6. Carlsson LA, Bottiger LE. Risk factors of ischemic heart disease in men and women. Results of the 19 year old follow up of the Stockholm prospective study. Acta Med Scand 1985;218:207-211
7. Aro J, Haapiaainen R, Sane T, et al. Effects of orchiectomy and polyestradiol phosphate on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients. Eur Urol 1990;17:229-235
8. von Schoultz B, Carlstrom J, Collste L, et al. Estrogen therapy and liver function - metabolic effects of oral and parenteral administration. Prostate 1989;14:389-395
9. Elkik F, Gompel A, Mercier BC, et al. Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in post-menopausal women. Am J Obstet Gynecol 1982;143:888-892
10. Geenen RWF, Delaere KPJ, Van Wersch JWJ. Hematological variables in prostate carcinoma patients. Acta Urol Belg 1996;64:21-26
11. Kohli M, Fink L, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study comparing activation markers of coagulation in ambulatory patients with advanced prostate cancer to age and healthy male controls. Blood Coagul Fibrinolysis 2002;13:1-5
12. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991;67:1377-1383
13. Abdlkadir SA, Carvalhal GF, Kaleem Z, et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000;31:443-447
14. Lwaleed BA, Francis JL, Chisholm M. Urinary tissue factor levels in patients with bladder and prostate cancer. Eur J Surg Oncol 2000;26:44-49
15. Adamson AS, Francis JL, Witherow R, Snell ME. Urinary tissue factor levels in transitional cell carcinoma of the bladder. J Urol 1992;148(2 Pt 1):449-452
16. Bromberg ME, Capello M. Cancer and blood coagulation: molecular aspects. Cancer J Sci Am 1999;5:132-138
17. Stone MJ, Ruf W, Miles DJ, Edington TS, Wright PE. Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and physical characterization. Biochem J 1995;310(Pt 2):605-614
18. Rao LMV, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987;69:645-651
19. Kataoka H, Uchino H, Asada Y, et al. Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver. Int J Cancer 1997;72:878-884
20. Werling RW, Zacharski LR, Kisiel W, et al. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993;69:366-369
21. Petersen LC, Sprecher CA, Foster DC, et al. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996;35:266-272
22. Konduri SD, Tasiou A, Chandrasekhar N, Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 2001;18:127-131
23. Carrel A, Burrows MT. Cultivation in vitro of malignant tumors. J Exp Med 1911;13:571-575
24. Cliffton EE, Grossi CE. Fibrinolytic activity of human tumors as measured by the fibrin plate method. Cancer 1955;8:1146-1154
25. Goldhaber P, Corman I, Ormsbee RA. Experimental alteration of the ability of tumor cells to lyse plasma clots in vitro. Proc Soc Exp Biol Med 1947;66:590-595
26. Tagnon HJ, Whitmore WF, Schulman P, Kravitc HC. The significance of fibrinolysis occurring in patients with metastatic prostate cancer. Cancer 1953;6:63-67
27. Thurston AV, Briant SL. Aspirin and post-prostatectomy hemorrhage. Br J Urol 1993;71:574-576
28. Carroll VA, Binder BR. The role of the plasminogen activation system in cancer. Semin Thromb Hemost 1999;25:183-197
29. Plow EF, Felez J, Miles LA. Cellular regulation of fibrinolysis. Thromb Haemost 1991;66:32-36
30. Åstedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 1976;261:595-597
31. Kirchheimer JC, Pflueger H, Ritschl P, Hienert G, Binder BR. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 1985;5:344-355
32. Kirchheimer JC, Binder BR, Pflueger H, Hienert G. Does plasma urokinase antigen reflect tumor urokinase in prostatic carcinoma? Thromb Haemost 1985;54:729
33. Duffy MJ, O'Grady P, Devaney D, et al. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988;62:531-533
34. Sappino AP, Busso N, Belin D, Vassali JD. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987;47:4043-4046
35. Corasanti JG, Celik C, Camiolo SM, et al. Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification. J Natl Cancer Inst 1980;65:345-351
36. De Bruin PA, Griffioen G, Verspaget HW, Verheijen JH, Earners CB. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987;47:4654-4657
37. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-2907
38. Hasui Y, Suzumiya J, Marutsuka K, et al. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. Cancer Res 1989;49:1067-1070
39. Hofmann R, Lehmer A, Hartung R, et al. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol 1996;155:858-862
40. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78:487-492
41. Camiolo SM, Markus G, Piver MS. Plasminogen activator content of gynecological tumors and their metastases. Gynecol Oncol 1987;26:364-373
42. Soszka T, Olszewsld K. Plasminogen activators and their inhibitors in normal, hyperplastic and carcinomatous human endometrium. Thromb Res 1986;42(Suppl):835-846
43. Wilson EL, Jacobs P, Francis GE, et al. Secretion of plasminogen activators by normal bone marrow cells and leukemic myeloid cells. Fibrinolysis 1992;6:77-79
44. Duffy MJ, O'Grady P, Devaney D, et al. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 1988;48:1348-1349
45. Gaylis FD, Keer HN, Wilson MJ, et al. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 1989;142:193-198
46. Keer HN, Gaylis FD, Kozlowski JM, et al. Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. Prostate 1991;18:201-214
47. Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994;54:2372-2377
48. Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 1995;63:840-845
49. Goltzman D, Bolivar I, Moroz LA, Rabbani SA. Studies on the pathogenesis of osteoblastic metastases by prostate cancer. Adv Exp Med Biol 1992;324:165-171
50. Hollas W, Hoosein N, Chung LWK, et al. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost 1992;68:662-666
51. Pedersen H, Schmitt M, Ronne E, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993;92:2160-2167
52. Miyake H, Hara I, Yamanaka K, et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999;39:123-129
53. Hienert G, Kirchheimer JC, Pflueger H, Binder BR. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 1988;140:1466-1469
54. Levin EG, Santell L. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J Cell Biol 1987;105(6 Pt 1):2543-2549
55. Laiho M, Saksela O, Andreasen PA, Keski OJ. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol 1986;103(6 Pt 1):2403-2410
56. Cubellis MV, Wun TC, Blsi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990;9:1079-1085
57. Del Rosso M, Fibbi G, Dini G, et al. Modulation of surface associated urokinase in different cell lines: evidence for urokinase interiorization and degradation. Semin Thromb Hemost 1991;17:262-267
58. Soff GA, Sanderowitz J, Gately S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995;96:2593-2600
59. Swiercz R, Keck RW, Skrzypczak JE, Selman SH, Jankun J. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 2001;8:463-470
60. Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumor growth through inhibition of apoptosis. Br J Cancer 2000;82:1702-1708
61. Foekens JA, Portengen H, Look MP, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994;12:1648-1658
62. Janicke F, Pache L, Schmitt M, et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994;54:2527-2530
63. Geeenen RWF, Delaere KPJ, van Wersch JW. Hematological variables in prostatic carcinoma patients. Acta Urol Belg 1996;64:21-26
64. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Review Nat Med 1995;1:27-31
65. Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329-2333
66. Huss WJ, Hanrahan CF, Barrios RJ, et al. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-2743
67. Jones A, Fujiyama C, Turner K, et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 2000;85:276-280
68. Duque JLF, Loughlin KR, Adam RM, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523-537
69. Haggstrom S, Bergh A, Damber J. Vascular endothelial growth factor content in metastasizing and non metastasizing Dunning prostate carcinoma. Prostate 2000;45:42-50
70. Wynendaele W, Derua R, Hoylaerts MF, et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 1999;10:965-971
71. Grand RJA, TurnellAS, Grabham PW. Cellular consequences of thrombin receptor activation. Biochem J 1996;313:353-368
72. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 2000;407:258-264
73. Brass S. Platelets and proteases. Nature 2000;413:26-27
74. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role of thrombin receptor signaling in endothelial cells during embryonic development. Science 2001;293:1666-1670
75. Rudroff C, Striegler S, Schilli M, Scheele J. Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1. Eur J Surg Oncol 2001;27:472-476
76. Klepfish A, Greco MA, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer 1993;53:978-982
77. Nierodzik ML, Bain RM, Liu LX, et al. Presence of seven transmembrane thrombin receptors on human tumor cells: effect of activation on tumor adhesion to platelets and tumor tyrosine phosphorylation. Br J Hematol 1996;92:452-457
78. Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in-vitro and metastasis in vivo. Cancer Res 1992;52:3267-3272
79. Harlabopolous GC, Grant DS, Kleinman HK, et al. Thrombin promotes endothelial cell alignment in matrigel in vitro and angiogenesis in vivo. Am J Physiol 1997;273:239-245
80. Herbert JM, Dupuy E, Laplace MC, et al. Thrombin induces endothelial growth via both a proteolytic and a non proteolytic pathway. Biochem J 1994;303:227-231
81. Tsopanoglou NE, Maragoudakis ME. On the endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem 1999;274:23969-23976
82. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P, Maragoudakis MM. Effects of thrombin/thrombosis in angiogenesis and turnout progression. Matrix Biol 2000;19:345-351
83. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblast, DU 145 prostate cells and CHRF megakaryocytes. Thromb Hemost 2001;86:1094-1098
84. Gately S, Twardowski P, Stack MS, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996;56:4887-4890